peldesine profile

peldesine: potent inhibitor of human CCRF-CEM T-cell proliferation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	135413525
CHEMBL ID	311300
SCHEMBL ID	61135
MeSH ID	M0272227

Synonym
peldesine [usan]
4h-pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)-
9-(3-pyridylmethyl)-7h-9-deazaguanine
CHEMBL311300 ,
bdbm50039542
2-amino-7-pyridin-3-ylmethyl-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
2-amino-7-(pyridin-3-ylmethyl)-3h-pyrrolo[3,2-d]pyrimidin-4(5h)-one
peldesine
bcx-34
133432-71-0
D05396
peldesine (usan)
2-amino-3,5-dihydro-7-(3-pyridylmethyl)-4h-pyrrolo(3,2-d)pyrimidin-4-one
DB02568
2-amino-7-(pyridin-3-ylmethyl)-3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
BC3 ,
2-amino-7-(pyridin-3-ylmethyl)-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
peldesine [usan:inn]
7b646rj70f ,
unii-7b646rj70f
SCHEMBL61135
peldesine [inn]
peldesine [mart.]
peldesine [who-dd]
2-amino-3,5-dihydro-7-(3-pyridylmethyl)-4h-pyrrolo[3,2-d]pyrimidin-4-one
2-amino-7-(3-pyridylmethyl)-4-oxo-3h,5h-pyrrolo[3,2-d]pyrimidine
DOHVAKFYAHLCJP-UHFFFAOYSA-N
2-amino-7-(3-pyridylmethyl)-4-oxo-3h,5h-pyrrolo[3.2-d]pyrimidine
DTXSID10158107
2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4h-pyrrolo[3,2-d]pyrimidin-4-one
peldesine,bcx-34
Q27093544
HY-106934
2-amino-7-(pyridin-3-ylmethyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
CS-0026946
2-amino-7-[(pyridin-3-yl)methyl]-1h,4h,5h-pyrrolo[3,2-d]pyrimidin-4-one
AKOS040734142

Excerpt	Reference
"Peldesine (BCX-34) is a potent inhibitor of the enzyme purine nucleoside phosphorylase (PNP). "	( Preformulation studies for the development of a parenteral liquid formulation of the immunomodulator, peldesine. Van Winkle, LL; Viegas, TX, )

Excerpt	Reference
"The pharmacokinetic parameters of peldesine (BCX-34) were investigated after single and multiple oral doses in two groups of healthy adult volunteers."	( Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. Kisicki, J; Omura, GA; Stoltz, RR; Viegas, TX, 2000)

Excerpt	Reference
" Oral bioavailability of BCX-34 in rats is 76%."	( In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Bantia, S; Johnson, HG; Montgomery, JA; Walsh, GM, 1996)
"0 h, and the absolute bioavailability of the oral formulation was approximately 51%."	( Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. Kisicki, J; Omura, GA; Stoltz, RR; Viegas, TX, 2000)

Excerpt	Reference
" The results demonstrate that BCX-34 inhibits human PNP and T-cell proliferation, is orally bioavailable in rodents, and pharmacologically active in vivo in rodents after oral dosing with no apparent side effects or toxicity."	( In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Bantia, S; Johnson, HG; Montgomery, JA; Walsh, GM, 1996)
" Serial blood samples and total urine outputs were collected during dosing and for at least 24 hours after the last dose was administered."	( Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers. Kisicki, J; Omura, GA; Stoltz, RR; Viegas, TX, 2000)

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Purine nucleoside phosphorylase	Homo sapiens (human)	IC50 (µMol)	0.2000	0.0035	1.4987	5.0000	AID459942
Purine nucleoside phosphorylase	Homo sapiens (human)	Ki	0.0135	0.0000	0.5289	7.0000	AID1571174
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
inosine catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
urate biosynthetic process	Purine nucleoside phosphorylase	Homo sapiens (human)
positive regulation of T cell proliferation	Purine nucleoside phosphorylase	Homo sapiens (human)
positive regulation of alpha-beta T cell differentiation	Purine nucleoside phosphorylase	Homo sapiens (human)
allantoin metabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
nucleobase-containing compound metabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
inosine catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
deoxyinosine catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
deoxyadenosine catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
purine ribonucleoside salvage	Purine nucleoside phosphorylase	Homo sapiens (human)
IMP catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
nicotinamide riboside catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
immune response	Purine nucleoside phosphorylase	Homo sapiens (human)
nucleotide biosynthetic process	Purine nucleoside phosphorylase	Homo sapiens (human)
response to xenobiotic stimulus	Purine nucleoside phosphorylase	Homo sapiens (human)
positive regulation of interleukin-2 production	Purine nucleoside phosphorylase	Homo sapiens (human)
purine-containing compound salvage	Purine nucleoside phosphorylase	Homo sapiens (human)
dAMP catabolic process	Purine nucleoside phosphorylase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleoside binding	Purine nucleoside phosphorylase	Homo sapiens (human)
purine nucleobase binding	Purine nucleoside phosphorylase	Homo sapiens (human)
purine-nucleoside phosphorylase activity	Purine nucleoside phosphorylase	Homo sapiens (human)
protein binding	Purine nucleoside phosphorylase	Homo sapiens (human)
phosphate ion binding	Purine nucleoside phosphorylase	Homo sapiens (human)
identical protein binding	Purine nucleoside phosphorylase	Homo sapiens (human)
guanosine phosphorylase activity	Purine nucleoside phosphorylase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Purine nucleoside phosphorylase	Homo sapiens (human)
cytoplasm	Purine nucleoside phosphorylase	Homo sapiens (human)
cytosol	Purine nucleoside phosphorylase	Homo sapiens (human)
secretory granule lumen	Purine nucleoside phosphorylase	Homo sapiens (human)
extracellular exosome	Purine nucleoside phosphorylase	Homo sapiens (human)
ficolin-1-rich granule lumen	Purine nucleoside phosphorylase	Homo sapiens (human)
cytoplasm	Purine nucleoside phosphorylase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID459941	Inhibition of Schistosoma mansoni purine nucleoside phosphorylase	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies.
AID164756	Inhibitory activity against calf spleen purine nucleoside phosphorylase (PNP) using inosine as substrate at a concentration of 10 uM.	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID229634	Selectivity ratio is evaluated as (IC50(50 mM PO4) / IC50(1 mM PO4)	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.
AID459943	Selectivity ratio of IC50 for Schistosoma mansoni purine nucleoside phosphorylase to IC50 for human purine nucleoside phosphorylase	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies.
AID156068	Inhibition of Purine nucleoside phosphorylase was evaluated against the enzyme from calf spleen in 50 mM phosphate	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.
AID459942	Inhibition of human purine nucleoside phosphorylase	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies.
AID164764	Inhibitory activity against calf spleen purine nucleoside phosphorylase (PNP) using inosine as substrate at a concentration of 10 uM.	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID164763	Inhibitory activity against calf spleen purine nucleoside phosphorylase (PNP) using 2-amino-6-mercapto-7-methyl purine ribonucleoside (MESG) as substrate.	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID164769	Tested for its ability to inhibit calf spleen purine nucleoside phosphorylase (PNP)	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.
AID229548	Ratio of IC50 values for guanine and related hypoxanthines in PNP inhibition assay	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.
AID1571174	Inhibition of human PNP	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	The transition to magic bullets - transition state analogue drug design.
AID156067	Inhibition of purine nucleoside phosphorylase against the enzyme from calf spleen in 1 mM phosphate	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.
AID229806	Ratio of Ki ino and Kimesg against purine nucleoside phosphorylase (PNP)	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID229272	Ratio of IC50 ino and Ki ino against purine nucleoside phosphorylase (PNP)	1999	Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13	Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	9 (52.94)	18.2507
2000's	6 (35.29)	29.6817
2010's	2 (11.76)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (16.67%)	5.53%
Reviews	2 (11.11%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (72.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.01	1	0	pyrrole; secondary amine
isopropyl myristate isopropyl myristate: used for microemulsions; structure	2	1	0	fatty acid ester
caprylates Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis.	2	1	0	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	1.99	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
1,4-dideoxy-1,4-iminoarabinitol, (2r-(2alpha,3beta,4beta))-isomer [no description available]	3.27	1	0	pyrrolidines
antimony Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.	2.01	1	0	metalloid atom; pnictogen
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	2.01	1	0	metalloid atom; pnictogen	micronutrient
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2.01	1	0
galidesivir [no description available]	3.27	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	1.99	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	3.27	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
deoxyguanosine [no description available]	3.79	2	1	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyguanosine triphosphate [no description available]	1.99	1	0	deoxyguanosine phosphate; guanyl deoxyribonucleotide; purine 2'-deoxyribonucleoside 5'-triphosphate	Arabidopsis thaliana metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	1.99	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanine [no description available]	7.34	13	3	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2	1	0	guanosines; purines D-ribonucleoside	fundamental metabolite
hypoxanthine [no description available]	1.98	1	0	nucleobase analogue; oxopurine; purine nucleobase	fundamental metabolite
inosine [no description available]	5.2	3	1	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
8-amino-9-(2-thienylmethyl)guanine [no description available]	3.81	3	0
8-amino-9-benzylguanine 8-amino-9-benzylguanine: structure given in first source	3.53	2	0
forodesine forodesine: structure in first source	3.56	2	0	dihydroxypyrrolidine; pyrrolopyrimidine
8-aminoguanine [no description available]	2.39	2	0
9-(4-hydroxybutyl)guanine [no description available]	1.98	1	0
acyclovir monophosphate [no description available]	3.27	1	0
immucillin g immucillin G: structure in first source	3.27	1	0	dihydroxypyrrolidine; pyrrolopyrimidine
ulodesine ulodesine: a purine nucleoside phosphorylase inhibitor	3.27	1	0
9-deaza-9-(3-thienylmethyl)guanine [no description available]	4.02	4	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.01	1	0

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	2.03	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.03	1	0
Leukemia, Lymphocytic, T Cell [description not available]	1.99	1	0
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	1.99	1	0
T-Cell Lymphoma [description not available]	1.99	1	0
Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.	1.99	1	0
Cancer of Skin [description not available]	3.38	1	1
Cutaneous T-Cell Lymphoma [description not available]	9.35	2	2
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.38	1	1
Skin Neoplasms Tumors or cancer of the SKIN.	3.38	1	1
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	4.35	2	2
Palmoplantaris Pustulosis [description not available]	2.92	1	0
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	2.92	1	0

peldesine

Description

Cross-References

Synonyms (37)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Biological Processes (17)

Molecular Functions (7)

Ceullar Components (6)

Bioassays (14)

Research

Studies (17)

Study Types

peldesine

Description

Cross-References

Synonyms (37)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Biological Processes (17)

Molecular Functions (7)

Ceullar Components (6)

Bioassays (14)

Research

Studies (17)

Study Types

Related Drugs (28)

Related Conditions (13)